Himani Goyal, MD
Ophthalmology · New York, NYNPI 1467637298
Payments from drug & device makers
Across 285 payments — averaging $457.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tarsus Pharmaceuticals, Inc.$87K
- Glaukos Corporation$16K
- Alcon$5K
- Bausch & Lomb Americas Inc.$4K
- Alcon Research LLC$3K
- Carl Zeiss Meditec, Inc.$3K
- plus $12K from 23 others
What the payments were for
- Consulting fees$43,97534%
- Speaking & faculty fees$67,17552%
- Travel & lodging$4,5043%
- Food & beverage$14,70211%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tarsus Pharmaceuticals, Inc. | 78 | $87,206 |
| Glaukos Corporation | 16 | $15,702 |
| Alcon | 48 | $4,844 |
| Bausch & Lomb Americas Inc. | 6 | $4,462 |
| Alcon Research LLC | 2 | $3,490 |
| Carl Zeiss Meditec, Inc. | 5 | $3,114 |
| Carl Zeiss Meditec Cataract Technology Inc. | 6 | $2,138 |
| Oyster Point Pharma, Inc. | 6 | $1,520 |
| Sight Sciences, Inc. | 12 | $1,012 |
| Johnson & Johnson Surgical Vision, Inc. | 8 | $956 |
| AbbVie | 12 | $816 |
| Sun Pharmaceutical Industries Inc. | 10 | $661 |
| Topcon Healthcare, Inc. | 2 | $595 |
| NEW World Medical,inc. | 7 | $587 |
| Harrow Eye, LLC | 11 | $581 |
| Johnson & Johnson Vision Care, Inc. | 3 | $462 |
| Eyevance Pharmaceuticals LLC | 3 | $459 |
| Ocular Therapeutix, Inc. | 16 | $385 |
| Dompe US, Inc. | 8 | $334 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 11 | $300 |
| Surgical Specialties Corporation (US), Inc. (dba Corza Medical) | 3 | $187 |
| Mallinckrodt Hospital Products Inc. | 2 | $181 |
| Aerie Pharmaceuticals, Inc. | 1 | $124 |
| Biotissue Holdings Inc. | 3 | $81 |
| Thea Pharma Inc. | 1 | $49 |
| Carl Zeiss Meditec USA, Inc. | 1 | $38 |
| Novartis | 2 | $37 |
| Ivantis, Inc | 1 | $19 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XDEMVY$66,147
- Epioxa$9,077
- Travoprost Intraocular Implant - iDose$5,706
- MIEBO$4,250
- XIIDRA$4,250
- Clareon$1,680
- IOLMaster$1,500
- VERACITY SURGICAL$1,500
- TYRVAYA$1,466
- NGENUITY$1,095
- CT Lucia$1,000
- CALLISTO eye$1,000
- miLOOP$1,000
- AcrySof IQ VIVITY$1,000
- Tecnis Simplicity$970
- STAR S4 IR$650
- Tecnis IOL$650
- Luxor$631
- OMNI(R) SURGICAL SYSTEM (US)$608
- XEN GLAUCOMA TREATMENT SYSTEM$557
How this compares
$130,356 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 118 | $216,923 |
| RestasisCyclosporine | 98 | $80,940 |
| XiidraLifitegrast | 33 | $36,512 |
| TyrvayaVarenicline Tartrate | 20 | $12,556 |
| Bromfenac Sodium | 55 | $11,658 |
| ProlensaBromfenac Sodium | 32 | $10,736 |
| LumiganBimatoprost | 11 | $4,042 |
| TobradexTobramycin/Dexamethasone | 13 | $3,421 |
| Ketorolac Tromethamine | 221 | $3,313 |
| Prednisolone Acetate | 86 | $3,289 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 13 | $2,992 |
| Timolol Maleate | 23 | $1,759 |
| Latanoprost | 104 | $1,129 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 30 | $734 |
| ValacyclovirValacyclovir Hcl | 18 | $731 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Tarsus Pharmaceuticals, Inc.Xdemvy | $87,206 | $216,923118 claims |
| AbbVieRestasis, Lumigan | $816 | $84,982109 claims |
| Bausch & Lomb Americas Inc.Xiidra | $4,462 | $36,51233 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $1,520 | $12,55620 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $300 | $10,73632 claims |
| AlconSimbrinza | $4,844 | $2,99213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in New York
- Douglas JabsNew York$24.3M
- Nathan RadcliffeNew York$2.4M
- Richard SpaideNew York$1.7M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
- Sharon KehNew York$941K
- Joshua YoungNew York$814K
- Joseph PanarelliNew York$704K
- Joshua KimNew York$677K
- Eric RosenbergNew York$526K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.